341 related articles for article (PubMed ID: 32923149)
1. Versatile chimeric antigen receptor platform for controllable and combinatorial T cell therapy.
Feldmann A; Hoffmann A; Bergmann R; Koristka S; Berndt N; Arndt C; Rodrigues Loureiro L; Kittel-Boselli E; Mitwasi N; Kegler A; Lamprecht C; González Soto KE; Bachmann M
Oncoimmunology; 2020 Jul; 9(1):1785608. PubMed ID: 32923149
[TBL] [Abstract][Full Text] [Related]
2. Targeting Acute Myeloid Leukemia Using the RevCAR Platform: A Programmable, Switchable and Combinatorial Strategy.
Kittel-Boselli E; Soto KEG; Loureiro LR; Hoffmann A; Bergmann R; Arndt C; Koristka S; Mitwasi N; Kegler A; Bartsch T; Berndt N; Altmann H; Fasslrinner F; Bornhäuser M; Bachmann MP; Feldmann A
Cancers (Basel); 2021 Sep; 13(19):. PubMed ID: 34638268
[TBL] [Abstract][Full Text] [Related]
3. Specific and safe targeting of glioblastoma using switchable and logic-gated RevCAR T cells.
Saleh HA; Mitwasi N; Ullrich M; Kubeil M; Toussaint M; Deuther-Conrad W; Neuber C; Arndt C; R Loureiro L; Kegler A; González Soto KE; Belter B; Rössig C; Pietzsch J; Frenz M; Bachmann M; Feldmann A
Front Immunol; 2023; 14():1166169. PubMed ID: 37122703
[TBL] [Abstract][Full Text] [Related]
4. Targeting colorectal cancer cells using AND-gated adaptor RevCAR T-cells.
Soto KEG; Loureiro LR; Bartsch T; Arndt C; Kegler A; Mitwasi N; Drewitz L; Hoffmann L; Saleh HA; Crespo E; Mehnert M; Daglar C; Abken H; Momburg F; Bachmann M; Feldmann A
Front Immunol; 2023; 14():1302354. PubMed ID: 38169746
[TBL] [Abstract][Full Text] [Related]
5. Next generation chimeric antigen receptor T cells: safety strategies to overcome toxicity.
Yu S; Yi M; Qin S; Wu K
Mol Cancer; 2019 Aug; 18(1):125. PubMed ID: 31429760
[TBL] [Abstract][Full Text] [Related]
6. Combining the best of two worlds: highly flexible chimeric antigen receptor adaptor molecules (CAR-adaptors) for the recruitment of chimeric antigen receptor T cells.
Darowski D; Kobold S; Jost C; Klein C
MAbs; 2019; 11(4):621-631. PubMed ID: 30892136
[TBL] [Abstract][Full Text] [Related]
7. Strategies for modifying the chimeric antigen receptor (CAR) to improve safety and reduce toxicity in CAR T cell therapy for cancer.
Sayadmanesh A; Yekehfallah V; Valizadeh A; Abedelahi A; Shafaei H; Shanehbandi D; Basiri M; Baradaran B
Int Immunopharmacol; 2023 Dec; 125(Pt A):111093. PubMed ID: 37897950
[TBL] [Abstract][Full Text] [Related]
8. Combined CD28 and 4-1BB Costimulation Potentiates Affinity-tuned Chimeric Antigen Receptor-engineered T Cells.
Drent E; Poels R; Ruiter R; van de Donk NWCJ; Zweegman S; Yuan H; de Bruijn J; Sadelain M; Lokhorst HM; Groen RWJ; Mutis T; Themeli M
Clin Cancer Res; 2019 Jul; 25(13):4014-4025. PubMed ID: 30979735
[TBL] [Abstract][Full Text] [Related]
9. Potential of Chimeric Antigen Receptor T-Cells in Cancer Therapy.
Desai D; Gaud RS; Shende P
Adv Exp Med Biol; 2021; 1326():39-46. PubMed ID: 33330963
[TBL] [Abstract][Full Text] [Related]
10. Recent advances in tumor associated carbohydrate antigen based chimeric antigen receptor T cells and bispecific antibodies for anti-cancer immunotherapy.
Rashidijahanabad Z; Huang X
Semin Immunol; 2020 Feb; 47():101390. PubMed ID: 31982247
[TBL] [Abstract][Full Text] [Related]
11. [Chimeric antigen receptors (CARs): universal tools in adoptive cell therapy].
Holzinger A; Abken H
Internist (Berl); 2021 Jun; 62(6):583-588. PubMed ID: 33928413
[TBL] [Abstract][Full Text] [Related]
12. [Cell therapy's poster child: Chimeric antigen receptor T cell therapy].
Qian L; Chen J; Wu X; Jing R; Sun J
Sheng Wu Gong Cheng Xue Bao; 2019 Dec; 35(12):2339-2349. PubMed ID: 31880140
[TBL] [Abstract][Full Text] [Related]
13. Novel adapter CAR-T cell technology for precisely controllable multiplex cancer targeting.
Seitz CM; Mittelstaet J; Atar D; Hau J; Reiter S; Illi C; Kieble V; Engert F; Drees B; Bender G; Krahl AC; Knopf P; Schroeder S; Paulsen N; Rokhvarguer A; Scheuermann S; Rapp E; Mast AS; Rabsteyn A; Schleicher S; Grote S; Schilbach K; Kneilling M; Pichler B; Lock D; Kotter B; Dapa S; Miltenyi S; Kaiser A; Lang P; Handgretinger R; Schlegel P
Oncoimmunology; 2021; 10(1):2003532. PubMed ID: 35686214
[TBL] [Abstract][Full Text] [Related]
14. Fourth-generation chimeric antigen receptor T cells targeting folate receptor alpha antigen expressed on breast cancer cells for adoptive T cell therapy.
Luangwattananun P; Junking M; Sujjitjoon J; Wutti-In Y; Poungvarin N; Thuwajit C; Yenchitsomanus PT
Breast Cancer Res Treat; 2021 Feb; 186(1):25-36. PubMed ID: 33389403
[TBL] [Abstract][Full Text] [Related]
15. Anti-CAR-engineered T cells for epitope-based elimination of autologous CAR T cells.
Koristka S; Ziller-Walter P; Bergmann R; Arndt C; Feldmann A; Kegler A; Cartellieri M; Ehninger A; Ehninger G; Bornhäuser M; Bachmann MP
Cancer Immunol Immunother; 2019 Sep; 68(9):1401-1415. PubMed ID: 31414180
[TBL] [Abstract][Full Text] [Related]
16. High-performance multiplex drug-gated CAR circuits.
Li HS; Wong NM; Tague E; Ngo JT; Khalil AS; Wong WW
Cancer Cell; 2022 Nov; 40(11):1294-1305.e4. PubMed ID: 36084652
[TBL] [Abstract][Full Text] [Related]
17. Chimeric Antigen Receptor Design Today and Tomorrow.
Boucher JC; Davila ML
Cancer J; 2021 Mar-Apr 01; 27(2):92-97. PubMed ID: 33750067
[TBL] [Abstract][Full Text] [Related]
18. Use of Cell and Genome Modification Technologies to Generate Improved "Off-the-Shelf" CAR T and CAR NK Cells.
Morgan MA; Büning H; Sauer M; Schambach A
Front Immunol; 2020; 11():1965. PubMed ID: 32903482
[TBL] [Abstract][Full Text] [Related]
19. Multi-antigen-targeted chimeric antigen receptor T cells for cancer therapy.
Han X; Wang Y; Wei J; Han W
J Hematol Oncol; 2019 Nov; 12(1):128. PubMed ID: 31783889
[TBL] [Abstract][Full Text] [Related]
20. Chimeric antigen-receptor T-cell therapy for hematological malignancies and solid tumors: Clinical data to date, current limitations and perspectives.
Gauthier J; Yakoub-Agha I
Curr Res Transl Med; 2017 Sep; 65(3):93-102. PubMed ID: 28988742
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
